|
|
 |
|
Viewing report
|
|
|
|
The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues
GBI Research, March 2010, Pages: 165
“The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues” provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Scope
The scope of this report includes:
- Annualized market data for the dermatology therapeutics market from 2001 to 2009, forecast forward to 2016
- Analysis of the leading therapeutic segments. These include Acne, Psoriasis, Dermatitis, Rosacea and Skin diseases.
- Analysis of the dermatology therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the dermatology therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, GlaxoSmithKline, Leo Pharma, Sanofi-Aventis, Genentech, Novartis AG, Johnson & Johnson, Galderma Pharma SA, and Merck & Co, Inc.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global dermatology therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges
Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets
Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials
Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
The Global Aesthetic Dermatology Market Outlook
Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
Global Atopic Dermatitis Drug Pipeline Capsule - 2012
Worldwide Dermatology Devices Market (2010 – 2015)
|
|
|
|
